Lymphoma Clinical Trials in Pennsylvania

Showing 161-180 of 668 trials

EchoTip AcuCore Post-Market Clinical Study

NCT06358001

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

AdenocarcinomaNeuroendocrine TumorsHepatocellular Carcinoma+5 more

Cook Research Incorporated183 participantsStarted Aug 2024

Orange, California, United States • Denver, Colorado, United States • Gainesville, Florida, United States +5 more locations

COMPLETEDPhase 295 miles

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

NCT02998476

The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Lymphoma

Incyte Corporation60 participantsStarted Mar 2017

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Tempe, Arizona, United States +67 more locations

EchoTip AcuCore Post-Market Clinical Study

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Lymphoma Trials in Other Cities

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Other Conditions in Pennsylvania